SCHEMBL9907343

SCHEMBL9907343

O=C(O)c1ccc2nccc(-c3cccc(Cl)c3Cl)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 1/20 0.42
TTR P02766 3/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4C Q9H3R0 2/20 0.40
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
SLC22A12 Q96S37 1/20 0.39
MAP4K4 O95819 1/20 0.38
TSHR P16473 1/20 0.38
KMO O15229 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PIM1 P11309 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907371 0.87 KMO (0.53) DOT1LTTRMRGPRX4MAPKAPK2ALDH1A1
SCHEMBL9907470 0.87 CSNK2A2 (0.41) TTRMAPKAPK2ALDH1A1POLBHPGD
SCHEMBL9907363 0.86 DOT1L (0.44) DOT1LTTRMAPKAPK2ALDH1A1POLB
SCHEMBL9907339 0.85 ALOX15 (0.49) DOT1LALDH1A1HPGDKDM4CTSHR
SCHEMBL9907792 0.83 HTR5A (0.51)
SCHEMBL9907344 0.81 HTR5A (0.43) DOT1LTTRMAPKAPK2MAP4K4KMO
SCHEMBL9907362 0.80 MAPKAPK2 (0.49) TTRMAPKAPK2ALDH1A1POLBKDM4C
SCHEMBL9907342 0.80 SRD5A2 (0.49) TTRMRGPRX4MAPKAPK2KDM4CNPC1
SCHEMBL9907387 0.80 MAPKAPK2 (0.45) TTRMAPKAPK2ALDH1A1POLBHPGD
SCHEMBL7918853 0.79 PLA2G2D (0.48) TTRMRGPRX4SLC22A12TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E DOT1L 785/4885TTR 3634/4885MRGPRX4 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.